Romidepsin
DCTPepD ID DCTPepD0027
Active Ingredients Romidepsin
Description A bicyclic depsipeptide antibiotic isolated from the bacterium Chromobacterium violaceum with antineoplastic activity. After intracellular activation, romidepsin binds to and inhibits histone deacetylase (HDAC), resulting in alterations in gene expression and the induction of cell differentiation, cell cycle arrest, and apoptosis. This agent also inhibits hypoxia-induced angiogenesis and depletes several heat shock protein 90 (Hsp90)-dependent oncoproteins.
Synonyms Antibiotic FR 901228; Depsipeptide; FK228; FR901228; Istodax; L-Valine, N- (3-hydroxy-7-mercapto-1-oxo-4-heptenyl)valyl- cysteinyl-2, 3-didehydro-2-aminobutanoyl-,xi-lactone, cyclic (1-2)-disulfide; N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4-1) Lactone, Cyclic; Romidepsin
Disease Cutaneous T Cell Lymphomas (CTCL)
Classification
HDAC inhibitor Peptide and derivative Cyclic
Structure Information
Molecular Formula C24H36N4O6S2
Molecular Weight 540.7
Active Sequence Not available
Sequence Length Not available
Modification Not available
IUPAC Name (1S,4S,7Z,10S,16Z,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
InChI InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17?,19-,20+/m1/s1
InChI_Key OHRURASPPZQGQM-KXOYPWAYSA-N
SMILES C/C=C(C(N[C@@H](C(C)C)C(O[C@H]1CC2=O)=O)=O)\NC(C(CSSCC/C=C/1)NC([C@H](N2)C(C)C)=O)=O
External Codes
PubChem CID 57515973
DrugBank Accession Number DB06176
NCI Thesaurus Code C1544
UNII CX3T89XQBK GSRS
CAS 128517-07-7
Drug approval
Drug indication
Romidepsin is indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy.
| Drug Name | Strength | Dosage Form/Route | Company | Marketing Status | Drug ID | Approval year |
|---|---|---|---|---|---|---|
| Istodax | 10mg/vial | Powder; Intravenous | Celgene | Prescription | NDA: 022393 | 2009 |
| Romidepsin | 10mg/vial | Powder; Intravenous | Fresenius Kabi Usa | Prescription | ANDA: 206254 | 2021 |
| Romidepsin | 10mg/2ml (5mg/ml) | Solution; Intravenous | Teva Pharms Usa Inc | Prescription | NDA: 208574 | 2020 |
| Romidepsin | 27.5mg/5.5ml (5mg/ml) | Solution; Intravenous | Teva Pharms Usa Inc | Prescription | NDA: 208574 | 2020 |
| Istodax | 10 mg / vial | Powder For Solution, Kit; Intravenous | Celgene Inc | Prescription | DIN: 02414295 | 2014 |
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT03770000 | An Open Label, Phase I/II Study to Evaluate the Safety and Efficacy of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor Given in Combination With a Histone Deacetylase (HDAC) Inhibitor, Romidepsin in Adult Patients With Relapsed/Refractory T-cell Lymphoma | T Cell Lymphoma | Phase 1/2 | Treatment |
| NCT01537744 | Phase I Trial of Oral 5-azacitidine With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma | Solid Tumors; Virally Mediated Cancers and Liposarcoma | Phase 1 | Treatment |
| NCT01353664 | An Open Label, Single-Arm Rollover Study for Subjects Who Participated In Other Romidepsin Protocols | Lymphoma; Cancer | Phase 2 | Treatment |
| NCT01913119 | A Pilot Study of Romidepsin in Relapsed or Refractory Extranodal NK/T-cell | Histologically Proven Extranodal NKTcell Lymphoma | Early Phase 1 | Treatment |
| NCT03355768 | Randomized Study of Romidepsin Versus the Combination of Romidepsin Plus Pralatrexate in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | Lymphoma, T-Cell, Peripheral | Phase 3 | Other |
More clinical information is obtained from ClinicalTrials.gov.
